PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Eur J Immunol. Author manuscript; available in PMC 2013 December 1.
Published in final edited form as:
PMCID: PMC3752658
NIHMSID: NIHMS492205

Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans

Abstract

Most Toll-like-receptors (TLRs) and interleukin-1 receptors (IL-1Rs) signal via myeloid differentiation primary response 88 (MyD88) and interleukin-1 receptor-associated kinase 4 (IRAK-4). The combined roles of these two receptor families in the course of experimental infections have been assessed in MyD88- and IRAK-4-deficient mice for almost fifteen years. These animals have been shown to be susceptible to 46 pathogens: 27 bacteria, 8 viruses, 7 parasites, and 4 fungi. Humans with inborn MyD88 or IRAK-4 deficiency were first identified in 2003. They suffer from naturally occurring life-threatening infections caused by a small number of bacterial species, although the incidence and severity of these infections decrease with age. Mouse TLR- and IL-1R-dependent immunity mediated by MyD88 and IRAK-4 seems to be vital to combat a wide array of experimentally administered pathogens at most ages. By contrast, human TLR- and IL-1R-dependent immunity mediated by MyD88 and IRAK-4 seems to be effective in the natural setting against only a few bacteria and is most important in infancy and early childhood. The roles of TLRs and IL-1Rs in protective immunity deduced from studies in mutant mice subjected to experimental infections should therefore be reconsidered in the light of findings for natural infections in humans carrying mutations as discussed in this review.

Keywords: Innate immunity, Toll-like receptors, MyD88, IRAK4, primary immunodeficiency, invasive pyogenic infections

Introduction

MyD88 was first described as a “macrophage differentiation marker” for which mRNA accumulated in murine M1 myeloleukemic cells upon activation with IL-6 [1, 2]. Human MYD88 maps to chromosome 3p22-p21.3 and contains five exons [1]. The full-length cDNA for human MYD88 encodes 296 amino acids forming a 33 kDa protein [2]. Murine Myd88 maps to chromosome 9q119. It also has five exons and the full-length cDNA encodes 296 amino acids forming a 33 kDa protein. The MyD88 protein includes an N-terminal “death domain” (DD) and a C-terminal Toll-interleukin receptor (TIR)-domain, similar to the intracellular domains of Toll-like receptors (TLRs) and members of the interleukin-1 receptor (IL-1R) superfamily, collectively referred to as TIR receptors [26]. Human IRAK4 maps to chromosome 12q12 and contains 13 exons. The full-length cDNA for human IRAK-4 encodes 460 amino acids, forming a 52 kDa protein. The murine Irak4 gene maps to chromosome 15q94 and also contains 13 exons. The corresponding full-length cDNA encodes 459 amino acids, forming a 52 kDa protein. The IRAK-4 protein contains an N-terminal DD and a central kinase domain (KD) [7].

MyD88 and IRAK-4 are essential for signaling via all TLRs with the exception of TLR3 and, to some extent, TLR4, and for signaling via most IL-1Rs, including IL-1R1, IL-18R and IL-33R (ST2) [817]. Following its activation, MyD88 binds to the IL-1Rs and TLRs via its TIR domain, forming an oligomer; it then recruits IRAK-4 to the receptor via its DD [5, 1821], mediating the activation of various transcription factors, including IRF5 and IRF7, AP-1 and NF-κB, depending in part on the cell type and the cell surface receptor stimulated [22] (see figure 1). Thus, TIR-MyD88-IRAK-4-mediated signaling appears to be important for the innate recognition of pathogens and the ignition of inflammation, and, as such, is indispensable for the induction of protective immunity.

Figure 1
MyD88- and IRAK-4-signaling pathways

However, most demonstrations of the importance of TIR-MyD88-IRAK-4-dependent pathways for protective immunity have been based on studies of experimental infections in mice in which protective immunity against a broad range of infectious agents has been shown; however, the essential nature of the role of TIR signaling in such broad-ranging immunity has been called into question by both clinical genetic and evolutionary genetic studies [2328]. In particular, the identification of human IRAK-4 and MyD88 deficiencies as immunological and clinical phenocopies has provided considerable insights [29, 30]. Detailed immunological and clinical descriptions of a large cohort of patients with these deficiencies have led to a reassessment of the importance of the TIR-MyD88-IRAK-4-dependent pathway for general protective immunity in humans under natural conditions [31].

Impact of MyD88 and IRAK-4 deficiencies on protective immunity in mice

Susceptibility to pathogens in Myd88- and Irak-4-deficient mice

Myd88-deficient mice are known to be susceptible to experimental infections with 45 pathogens: 27 bacteria [3277], eight viruses [7891], seven protozoa [92107], and four fungi [108113]. Enhanced pathogen growth in Myd88-deficient mice has been observed for:

  1. Six Gram-positive bacteria: Bacillus anthracis (spores injected subcutaneously (s.c.)) [77], Listeria monocytogenes after intravenous (i.v.) or intraperitoneal (i.p.) injection or infection via gavage [33, 34, 38, 59], Staphylococcus aureus after i.v. or s.c. injection [32, 50], Streptococcus agalacticae after s.c. or i.p. injection [37], Streptococcus pneumoniae after i.v. or intranasal (i.n.) infection [45, 48], Streptococcus pyogenes after s.c. injection [72];
  2. Eighteen Gram-negative bacteria: Anaplasmataceae after i.p. injection [73], Borrelia burgdorferi after intradermal (i.d.) inoculation [42, 43, 51], Borrelia hermsii after i.p. injection [52], Brucella abortus after i.p. injection [46, 64], Burkholderia pseudomallei after i.n. inoculation [67], Campylobacter jejunii after stomach gavage [60], Chlamydia muridarum after i.n. inoculation [71], Chlamydia pneumoniae after i.n. application [47], Citrobacter koseri after the direct inoculation of live bacteria into the brain parenchyma by stereotactic injection [76], Citrobacter rodentium after ingestion of a suspension of the bacterium or gavage [61, 62], Franciscella tularensis after i.n. inoculation and i.d. deposition [53, 68], Haemophilus influenzae after i.n. inoculation or i.p. injection [49, 66], Klebsiella pneumoniae after intratracheal (i.t.) inoculation [69], Legionella pneumoniae after exposure to aerosols or after i.n. inoculation [54, 55], Mycoplasma pneumoniae after i.n. inoculation [74], Neisseria meningitidis after i.p. injection [56], Pseudomonas aeruginosa after exposure to aerosolized bacteria or i.n. inoculation [36, 44, 57, 63], Salmonella typhimurium after i.v. injection [70, 75];
  3. Three mycobacteria after i.v., i.n. or aerogenic exposure (Mycobacterium avium, Mycobacterium bovis, Mycobacterium tuberculosis) [35, 3941, 58, 65];
  4. Eight viruses: Herpes simplex virus type 1 after aerogenic exposure [80], Herpes simplex virus type 2 after vaginal challenge [83], Influenza A virus after i.n. inoculation [84], Lymphocytic choriomeningitis virus after i.v. injection [81, 85], Murine cytomegalovirus after i.p. injection [78, 79, 82, 86], Rabies virus after intracranial injection [90, 91], SARS coronavirus after i.n. inoculation [89], Vesicular stomatitis virus after i.n. inoculation or i.v. injection [87, 88];
  5. Seven parasites: Cryptosporidium parvum after gavage [101], Enterocytozoon bieneusi after oral inoculation [107], Leishmania braziliensis after the s.c. injection of stationary-phase promastigotes [104], Leishmania major after the s.c. injection of stationary-phase promastigotes [94, 95, 105], Toxoplasma gondii after i.p. injection [92, 93, 96, 98, 103, 106], Trypanosoma brucei after i.p. infection [99], Trypanosoma cruzii after i.p. injection [97, 100, 102];
  6. Four fungi: Aspergillus after i.v. infection [108], Candida albicans after i.v or intragastric injection [108, 109, 112], Cryptococcus neoformans after i.n. inoculation or i.p. injection [110, 111], Paracoccidioides brasiliensis after i.t. inoculation [113] (see Table 1).
    Table 1
    46 pathogens displaying higher growth rates in vivo in MyD88-deficient mice than in wild-type controls, in experimental conditions.

IRAK-4-deficient mice showed enhanced pathogen growth when challenged with Staphylococcus aureus i.p. [17].

Survival of MyD88- and IRAK-4-deficient mice

As greater pathogen growth in vivo is not always correlated with lower levels of survival, we consider here the published mortality data for experimental infections of MyD88-deficient mice. Mortality due to experimental infections was greater in MyD88-deficient mice than in wild-type mice for 33 pathogens:

  1. Six Gram-positive bacteria: Bacillus anthracis after i.p. injection of the toxin [77], Listeria monocytogenes after i.v injection [33], Staphylococcus aureus after i.v injection [32], Streptococcus agalacticae after s.c. or i.p. injection [37], Streptococcus pneumoniae after i.v. or i.n. infection [45, 48], Streptococcus pyogenes after s.c. injection [72];
  2. Eight Gram-negative bacteria: Anaplasmataceae after i.p. injection [73], Borrelia hermsii after i.p. injection [52], Burkholderia pseudomallei after i.n. inoculation [67], Chlamydia muridarum after i.n. inoculation [71], Chlamydia pneumoniae after i.n. application [47], Franciscella tularensis after i.n. inoculation and i.d. deposition [53, 68], Klebsiella pneumoniae after i.t. inoculation [69], Pseudomonas aeruginosa after exposure to aerosolized bacteria or i.n. inoculation [36, 44, 57, 63];
  3. Three mycobacteria after i.v., i.n. or aerogenic exposure (Mycobacterium avium, Mycobacterium bovis, Mycobacterium tuberculosis) [35, 39-41, 58];
  4. Eight viruses: Herpes simplex virus type 1 after aerogenic exposure [80], Herpes simplex virus type 2 after vaginal challenge [83], Influenza A virus after i.n. inoculation [84], Lymphocytic choriomeningitis virus after i.v. injection [81, 85], Murine cytomegalovirus after i.p. injection [78, 82], Rabies virus after intracranial injection [90, 91], SARS coronavirus after i.n. inoculation [89], Vesicular stomatitis virus after i.n. inoculation or i.v. injection [87, 88];
  5. Four parasites: Cryptosporidium parvum after gavage [101], Toxoplasma gondii after i.p. injection [92, 93, 96, 98, 103, 106], Trypanosoma brucei after i.p. infection [99], Trypanosoma cruzii after i.p. injection [97, 102];
  6. Four fungi: Aspergillus after i.v. infection [108], Candida albicans after i.v. or intragastric injection [108, 109, 112], Cryptococcus neoformans after i.n. inoculation or i.p. injection [110, 111], Paracoccidioides brasiliensis after i.t. inoculation [113] (see Table 2).
    Table 2
    33 pathogens for which the mortality of MyD88-deficient mice in vivo was greater than that of wild-type controls in experimental conditions

IRAK-4-deficient mice displayed lower levels of survival than wild-type mice following i.p. challenge with Staphylococcus aureus [17].

Impact of MyD88- and IRAK-4 deficiencies on protective immunity in humans

Susceptibility to pathogens in MyD88- and IRAK-4-deficient patients

The initial description of human IRAK-4 deficiency was based on three patients [29] and that of human MyD88 deficiency was based on nine patients [30]. These patients all carried either homozygous or compound heterozygous mutations of the IRAK4 or MYD88 gene that lead to nonfunctional proteins [29, 30]. Given these small numbers of patients, only brief preliminary conclusions could be made concerning the infectious phenotype associated with the absence of MyD88-IRAK-4-dependent signaling. The cumulative evidence from the large number of case reports since published and from the comprehensive description of a cohort of 76 patients (52 with IRAK-4 deficiency and 24 with MyD88 deficiency) allow firmer conclusions about the infectious phenotype in the absence of MyD88-IRAK-4-dependent signaling to be drawn [31, 114129]. There are also an additional five patients with IRAK-4 deficiency and two patients with MyD88 deficiency for whom no data have yet been published. The infectious phenotype of MyD88- and IRAK-4-deficient patients is dominated by invasive pyogenic infections. The most frequent of such infections are meningitis, sepsis, arthritis and osteomyelitis, and the principal bacteria isolated in cases of invasive infection are Streptococcus pneumoniae, Staphylococcus aureus and Pseudmomonas aeruginosa (for a list of all the pathogens isolated from Myd88- and IRAK-4-deficient patients, see Table 3). These patients also typically suffer from deep tissue infections of the upper respiratory tract, such as severe tonsillitis due to Pseudomonas aeruginosa in particular, and superficial skin infections, mostly caused by Staphylococcus aureus. We cannot rule out the possibility that the predominance of Gram-positive bacteria in patients with MyD88 and IRAK-4 deficiencies results at least in part from a patient recruitment bias. No patients with these deficiencies have yet been identified on the Indian subcontinent, in South America or in China. Patients with MyD88- or IRAK-4-deficiencies in these areas of the world might perhaps present a higher frequency of infections with Gram-negative bacteria, as suggested by case reports of invasive infection with Shigella spp. during endemic diarrhea outbreaks [119, 127]. However, by contrast to this uncertainty concerning positive associations about the infectious phenotype, we can highlight much more emphatically the negative associations drawn concerning the roles of MyD88 and IRAK-4 in host anti-pathogen defense. Most, if not all, of the 76 patients identified to date have been exposed to mycobacteria, viruses, Toxoplasma, Pneumocystis and other fungi, but none of these pathogens caused invasive infection. This strongly suggests that MyD88 and IRAK-4 are dispensable in humans for defense against these pathogens, contrary to expectations based on the results obtained in the mouse model [31].

Table 3
Invasive infections in patients with impaired MyD88-IRAK-4 signaling caused by six Gram-positive and 13 Gram-negative bacteria.

Survival of MyD88- and IRAK-4-deficient patients

At the time of writing, 24 patients with MyD88 deficiency have been identified (22 published [31], 2 unpublished (von Bernuth, unpublished)). Nine of these patients have died since identification: five in infancy and four in early childhood. The youngest of these nine patients died at one month of age and the oldest died at four years of age. The 15 surviving patients are currently four, seven, 11, 14 and 20 years old. Fifty-two patients with IRAK-4 deficiency have been identified [31]. Twenty-one of these patients have died since identification: 10 in infancy and 11 in early childhood. The youngest of these 19 patients was two months old, and the oldest was seven years old, at the time of death; the latter being patient P23 from the large cohort published in 2010 [31] who recently died of S. pneumoniae meningitis (unpublished observation). The 31 surviving patients are currently two (two patients), three (one patient), four (one patient), five (two patients), six (two patients), seven (three patients), nine (one patient), 12 (one patient), 13 (two patients), 14 (two patients), 15 (two patients), 16 (two patients), 17 (two patients), 18 (one patient), 20 (one patient), 21 (one patient), 22 (one patient), 30 (one patient), 33 (two patients) and 38 (one patient) years old [31]. Thus, it can clearly be seen that human MyD88- and IRAK-4-deficiencies are life-threatening. MyD88 and IRAK-4 are indispensable for survival in infancy and early childhood and, before the advent of vaccines and antibiotics, most if not all children with these defects would have died in the first few years of life. However, several individuals with MyD88 deficiency or its immunological phenocopy, IRAK-4-deficiency, who were given antibiotic prophylaxis and even sometimes IgG substitution following the genetic identification of the disease, have survived into adolescence and adulthood. Many of these patients have since stopped taking regular antibiotic prophylaxis, but have not yet developed invasive pyogenic infections. MyD88-IRAK-4-dependent signaling, therefore, appears to be dispensable for survival after adolescence.

Closing remarks

The notion that TLR- and IL-1R-mediated innate immune recognition is indispensable for survival and protective defense against many pathogens — based largely on findings in mouse models of experimental infections — should be reconsidered in light of the naturally occurring infections in humans with MyD88- or IRAK-4-deficiency. By contrast to the broad susceptibility of MyD88-deficient mice to 46 different bacteria, viruses, protozoa and fungi (i.e. to almost nearly all the microbes tested), patients with MyD88- or IRAK-4-deficiencies are susceptible to invasive and non-invasive infections with only a few Gram-positive and Gram-negative bacteria. Moreover, MyD88-IRAK-4-mediated TLR and IL-1R immunity is undoubtedly vital in infancy and early childhood, but gradually becomes dispensable, from adolescence onwards. Overall, MyD88-dependent TLR and IL-1R immunity is vital in both mice and humans, but its role in the course of naturally occurring infections in humans seems to be much more restricted than initially inferred from experimental infections in mice, as humans lacking functional MyD88 or IRAK-4 proteins are susceptible to a narrow range of pathogens, and only in infancy and early childhood. The different outcomes between experimental infections in mice and natural infections in humans may be due to species-specific differences, or more likely to differences in the modes of infection. In that regard, the study of naturally occurring infections in MyD88- and IRAK-4-deficient mice would be insightful, as suggested by preliminary studies [132]. In any case, the studies of MyD88- and IRAK4-deficient humans neatly illustrate the value of dissecting inborn errors of immunity underlying pediatric infectious diseases for deciphering the redundant and non-redundant roles of host defense genes in natura [2328]. Immunological redundancy is greater in the course of natural infections in outbred human populations than in the course of experimental infections in inbred mice. Genetic studies of this type will facilitate the burgeoning, long-awaited investigation of the contribution of immunity to health and disease in humans [131133].

Acknowledgments

We thank all patients, their families and physicians for their trust and cooperation. We thank Pegah Ghandil, Cheng-Lung Ku, Maya Chrabieh, Jacqueline Feinberg and Laurent Abel, members of the laboratory for Human Genetics of Infectious Diseases, Paris and Anne-Hélène Lebrun, Michael Bauer and Karoline Strehl, members of Kinderklinik mit Schwerpunkt Pneumologie und Immunologie, Berlin for critically reading the manuscript. The Laboratory of Human Genetics of Infectious Diseases is supported by grants from The Rockefeller University Center for Clinical and Translational Science (5UL1RR024143-03) and The Rockefeller University. The Laboratory of Human Genetics of Infectious Diseases was supported by the March of Dimes, the Dana Foundation, the ANR, INSERM, and PHRC. HvB received funding from the University San Raffaele (Milan, Italy), the Legs Poix (Paris, France), the Deutsche Forschungsgemeinschaft (DFG VO 995/1-1, VO 995/1-2). HvB receives ongoing support by the Deutsche Forschungsgemeinschaft (DFG BE 3895/3-1) (Bonn, Germany), the Bundesministerium für Bildung und Forschung (PID-NET) (Berlin, Germany), the Sonnenfeldstiftung (Berlin) and intramural funding from the Medical Faculty, Charité, Berlin.

References

1. Hardiman G, Jenkins NA, Copeland NG, Gilbert DJ, Garcia DK, Naylor SL, Kastelein RA, Bazan JF. Genetic structure and chromosomal mapping of MyD88. Genomics. 1997;45:332–339. [PubMed]
2. Hardiman G, Rock FL, Balasubramanian S, Kastelein RA, Bazan JF. Molecular characterization and modular analysis of human MyD88. Oncogene. 1996;13:2467–2475. [PubMed]
3. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature. 1991;351:355–356. [PubMed]
4. Whitham S, Dinesh-Kumar SP, Choi D, Hehl R, Corr C, Baker B. The product of the tobacco mosaic virus resistance gene N: similarity to toll and the interleukin-1 receptor. Cell. 1994;78:1101–1115. [PubMed]
5. Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, Di Marco F, French L, Tschopp J. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem. 1998;273:12203–12209. [PubMed]
6. Bowie A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol. 2000;67:508–514. [PubMed]
7. Li S, Strelow A, Fontana EJ, Wesche H. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A. 2002;99:5567–5572. [PubMed]
8. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998;9:143–150. [PubMed]
9. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA., Jr MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253–258. [PubMed]
10. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999;11:115–122. [PubMed]
11. Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, Monaco C, Feldmann M, Foxwell BM. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood. 2004;103:2229–2237. [PubMed]
12. Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A. 2004;101:3533–3538. [PubMed]
13. Li X, Qin J. Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med. 2005;83:258–266. [PubMed]
14. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490. [PubMed]
15. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A. 2007;104:18660–18665. [PubMed]
16. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, Okayama Y, Akira S, Saito H, Galli SJ, Nakae S. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007;82:1481–1490. [PubMed]
17. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature. 2002;416:750–756. [PubMed]
18. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997;7:837–847. [PubMed]
19. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science. 1997;278:1612–1615. [PubMed]
20. Motshwene PG, Moncrieffe MC, Grossmann JG, Kao C, Ayaluru M, Sandercock AM, Robinson CV, Latz E, Gay NJ. An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem. 2009;284:25404–25411. [PubMed]
21. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465:885–890. [PMC free article] [PubMed]
22. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–384. [PubMed]
23. Casanova JL, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol. 2004;4:55–66. [PubMed]
24. Ku CL, Yang K, Bustamante J, Puel A, von Bernuth H, Santos OF, Lawrence T, Chang HH, Al-Mousa H, Picard C, Casanova JL. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev. 2005;203:10–20. [PubMed]
25. Quintana-Murci L, Alcais A, Abel L, Casanova JL. Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat Immunol. 2007;8:1165–1171. [PubMed]
26. Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science. 2007;317:617–619. [PubMed]
27. Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann N Y Acad Sci. 2010;1214:18–33. [PubMed]
28. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29:447–491. [PubMed]
29. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, Casanova JL. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299:2076–2079. [PubMed]
30. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, Herrero-Mata MJ, Arostegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yague J, Anton J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Marodi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, Casanova JL. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008;321:691–696. [PMC free article] [PubMed]
31. Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, Arkwright PD, McDonald D, Geha RS, Takada H, Krause JC, Creech CB, Ku CL, Ehl S, Marodi L, Al-Muhsen S, Al-Hajjar S, Al-Ghonaium A, Day-Good NK, Holland SM, Gallin JI, Chapel H, Speert DP, Rodriguez-Gallego C, Colino E, Garty BZ, Roifman C, Hara T, Yoshikawa H, Nonoyama S, Domachowske J, Issekutz AC, Tang M, Smart J, Zitnik SE, Hoarau C, Kumararatne DS, Thrasher AJ, Davies EG, Bethune C, Sirvent N, de Ricaud D, Camcioglu Y, Vasconcelos J, Guedes M, Vitor AB, Rodrigo C, Almazan F, Mendez M, Arostegui JI, Alsina L, Fortuny C, Reichenbach J, Verbsky JW, Bossuyt X, Doffinger R, Abel L, Puel A, Casanova JL. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010;89:403–425. [PMC free article] [PubMed]
32. Takeuchi O, Hoshino K, Akira S. Cutting Edge: TLR2-Deficient and MyD88-Deficient Mice Are Highly Susceptible to Staphylococcus aureus Infection. J Immunol. 2000;165:5392–5396. [PubMed]
33. Seki E, Tsutsui H, Tsuji NM, Hayashi N, Adachi K, Nakano H, Futatsugi-Yumikura S, Takeuchi O, Hoshino K, Akira S, Fujimoto J, Nakanishi K. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J Immunol. 2002;169:3863–3868. [PubMed]
34. Edelson BT, Unanue ER. MyD88-Dependent but Toll-Like Receptor 2-Independent Innate Immunity to Listeria: No Role for Either in Macrophage Listericidal Activity. J Immunol. 2002;169:3869–3875. [PubMed]
35. Feng CG, Scanga CA, Collazo-Custodio CM, Cheever AW, Hieny S, Caspar P, Sher A. Mice lacking myeloid differentiation factor 88 display profound defects in host resistance and immune responses to Mycobacterium avium infection not exhibited by Toll-like receptor 2 (TLR2)- and TLR4-deficient animals. J Immunol. 2003;171:4758–4764. [PubMed]
36. Skerrett SJ, Liggitt HD, Hajjar AM, Wilson CB. Cutting edge: myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus. J Immunol. 2004;172:3377–3381. [PubMed]
37. Mancuso G, Midiri A, Beninati C, Biondo C, Galbo R, Akira S, Henneke P, Golenbock D, Teti G. Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease. J Immunol. 2004;172:6324–6329. [PubMed]
38. Torres D, Barrier M, Bihl F, Quesniaux VJ, Maillet I, Akira S, Ryffel B, Erard F. Toll-like receptor 2 is required for optimal control of Listeria monocytogenes infection. Infect Immun. 2004;72:2131–2139. [PMC free article] [PubMed]
39. Nicolle DM, Pichon X, Bouchot A, Maillet I, Erard F, Akira S, Ryffel B, Quesniaux VF. Chronic pneumonia despite adaptive immune response to Mycobacterium bovis BCG in MyD88-deficient mice. Lab Invest. 2004;84:1305–1321. [PubMed]
40. Scanga CA, Bafica A, Feng CG, Cheever AW, Hieny S, Sher A. MyD88-Deficient Mice Display a Profound Loss in Resistance to Mycobacterium tuberculosis Associated with Partially Impaired Th1 Cytokine and Nitric Oxide Synthase 2 Expression. Infect Immun. 2004;72:2400–2404. [PMC free article] [PubMed]
41. Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF, Ryffel B. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest. 2004;114:1790–1799. [PMC free article] [PubMed]
42. Liu N, Montgomery RR, Barthold SW, Bockenstedt LK. Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in Borrelia burgdorferi-infected mice. Infect Immun. 2004;72:3195–3203. [PMC free article] [PubMed]
43. Bolz DD, Sundsbak RS, Ma Y, Akira S, Kirschning CJ, Zachary JF, Weis JH, Weis JJ. MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. J Immunol. 2004;173:2003–2010. [PubMed]
44. Power MR, Peng Y, Maydanski E, Marshall JS, Lin TJ. The development of early host response to Pseudomonas aeruginosa lung infection is critically dependent on myeloid differentiation factor 88 in mice. J Biol Chem. 2004;279:49315–49322. [PubMed]
45. Albiger B, Sandgren A, Katsuragi H, Meyer-Hoffert U, Beiter K, Wartha F, Hornef M, Normark S, Normark BH. Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol. 2005;7:1603–1615. [PubMed]
46. Weiss DS, Takeda K, Akira S, Zychlinsky A, Moreno E. MyD88, but not toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus. Infect Immun. 2005;73:5137–5143. [PMC free article] [PubMed]
47. Naiki Y, Michelsen KS, Schroder NW, Alsabeh R, Slepenkin A, Zhang W, Chen S, Wei B, Bulut Y, Wong MH, Peterson EM, Arditi M. MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia. J Biol Chem. 2005;280:29242–29249. [PubMed]
48. Khan AQ, Chen Q, Wu ZQ, Paton JC, Snapper CM. Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on toll-like receptor 2. Infect Immun. 2005;73:298–307. [PMC free article] [PubMed]
49. Wieland CW, Florquin S, Maris NA, Hoebe K, Beutler B, Takeda K, Akira S, van der Poll T. The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung. J Immunol. 2005;175:6042–6049. [PubMed]
50. Miller LS, O’Connell RM, Gutierrez MA, Pietras EM, Shahangian A, Gross CE, Thirumala A, Cheung AL, Cheng G, Modlin RL. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity. 2006;24:79–91. [PubMed]
51. Behera AK, Hildebrand E, Bronson RT, Perides G, Uematsu S, Akira S, Hu LT. MyD88 deficiency results in tissue-specific changes in cytokine induction and inflammation in interleukin-18-independent mice infected with Borrelia burgdorferi. Infect Immun. 2006;74:1462–1470. [PMC free article] [PubMed]
52. Bolz DD, Sundsbak RS, Ma Y, Akira S, Weis JH, Schwan TG, Weis JJ. Dual role of MyD88 in rapid clearance of relapsing fever Borrelia spp. Infect Immun. 2006;74:6750–6760. [PMC free article] [PubMed]
53. Collazo CM, Sher A, Meierovics AI, Elkins KL. Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intra-macrophage bacterial replication. Microbes Infect. 2006;8:779–790. [PubMed]
54. Hawn TR, Smith KD, Aderem A, Skerrett SJ. Myeloid differentiation primary response gene (88)- and toll-like receptor 2-deficient mice are susceptible to infection with aerosolized Legionella pneumophila. J Infect Dis. 2006;193:1693–1702. [PubMed]
55. Archer KA, Roy CR. MyD88-dependent responses involving toll-like receptor 2 are important for protection and clearance of Legionella pneumophila in a mouse model of Legionnaires’ disease. Infect Immun. 2006;74:3325–3333. [PMC free article] [PubMed]
56. Plant L, Wan H, Jonsson AB. MyD88-dependent signaling affects the development of meningococcal sepsis by nonlipooligosaccharide ligands. Infect Immun. 2006;74:3538–3546. [PMC free article] [PubMed]
57. Power MR, Marshall JS, Yamamoto M, Akira S, Lin TJ. The myeloid differentiation factor 88 is dispensable for the development of a delayed host response to Pseudomonas aeruginosa lung infection in mice. Clin Exp Immunol. 2006;146:323–329. [PubMed]
58. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I, Jacobs M, Ryffel B, Quesniaux VF. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol. 2007;179:1178–1189. [PubMed]
59. Brandl K, Plitas G, Schnabl B, Dematteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII{gamma} and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007;204:1891–1900. [PMC free article] [PubMed]
60. Watson RO, Novik V, Hofreuter D, Lara-Tejero M, Galan JE. A MyD88-deficient mouse model reveals a role for Nramp1 in Campylobacter jejuni infection. Infect Immun. 2007;75:1994–2003. [PMC free article] [PubMed]
61. Lebeis SL, Bommarius B, Parkos CA, Sherman MA, Kalman D. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol. 2007;179:566–577. [PubMed]
62. Gibson DL, Ma C, Bergstrom KS, Huang JT, Man C, Vallance BA. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol. 2007 [PubMed]
63. Skerrett SJ, Wilson CB, Liggitt HD, Hajjar AM. Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol. 2007;292:L312–322. [PubMed]
64. Macedo GC, Magnani DM, Carvalho NB, Bruna-Romero O, Gazzinelli RT, Oliveira SC. Central Role of MyD88-Dependent Dendritic Cell Maturation and Proinflammatory Cytokine Production to Control Brucella abortus Infection. J Immunol. 2008;180:1080–1087. [PubMed]
65. Hölscher C, Reiling N, Schaible UE, Hölscher A, Bathmann C, Korbel D, Lenz I, Sonntag T, Kröger S, Akira S, Mossmann H, Kirschning CJ, Wagner H, Freudenberg M, Ehlers S. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function of TLR2, -4 and -9. Eur J Immunol. 2008;38 [PubMed]
66. Hernandez M, Leichtle A, Pak K, Ebmeyer J, Euteneuer S, Obonyo M, Guiney DG, Webster NJ, Broide DH, Ryan AF, Wasserman SI. Myeloid differentiation primary response gene 88 is required for the resolution of otitis media. J Infect Dis. 2008;198:1862–1869. [PMC free article] [PubMed]
67. Wiersinga WJ, Wieland CW, Roelofs JJ, van der Poll T. MyD88 dependent signaling contributes to protective host defense against Burkholderia pseudomallei. PLoS One. 2008;3:e3494. [PMC free article] [PubMed]
68. Abplanalp AL, Morris IR, Parida BK, Teale JM, Berton MT. TLR-dependent control of Francisella tularensis infection and host inflammatory responses. PLoS One. 2009;4:e7920. [PMC free article] [PubMed]
69. Cai S, Batra S, Shen L, Wakamatsu N, Jeyaseelan S. Both TRIF- and MyD88-dependent signaling contribute to host defense against pulmonary Klebsiella infection. J Immunol. 2009;183:6629–6638. [PMC free article] [PubMed]
70. Talbot S, Totemeyer S, Yamamoto M, Akira S, Hughes K, Gray D, Barr T, Mastroeni P, Maskell DJ, Bryant CE. Toll-like receptor 4 signalling through MyD88 is essential to control Salmonella enterica serovar typhimurium infection, but not for the initiation of bacterial clearance. Immunology. 2009;128:472–483. [PubMed]
71. Zhang X, Gao L, Lei L, Zhong Y, Dube P, Berton MT, Arulanandam B, Zhang J, Zhong G. A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol. 2009;183:1291–1300. [PMC free article] [PubMed]
72. Loof TG, Goldmann O, Gessner A, Herwald H, Medina E. Aberrant inflammatory response to Streptococcus pyogenes in mice lacking myeloid differentiation factor 88. Am J Pathol. 2010;176:754–763. [PubMed]
73. Koh YS, Koo JE, Biswas A, Kobayashi KS. MyD88-dependent signaling contributes to host defense against ehrlichial infection. PLoS One. 2010;5:e11758. [PMC free article] [PubMed]
74. Lai JF, Zindl CL, Duffy LB, Atkinson TP, Jung YW, van Rooijen N, Waites KB, Krause DC, Chaplin DD. Critical role of macrophages and their activation via MyD88-NFkappaB signaling in lung innate immunity to Mycoplasma pneumoniae. PLoS One. 2010;5:e14417. [PMC free article] [PubMed]
75. Seibert SA, Mex P, Kohler A, Kaufmann SH, Mittrucker HW. TLR2-, TLR4- and Myd88-independent acquired humoral and cellular immunity against Salmonella enterica serovar Typhimurium. Immunol Lett. 2010;127:126–134. [PubMed]
76. Liu S, Kielian T. MyD88 is pivotal for immune recognition of Citrobacter koseri and astrocyte activation during CNS infection. J Neuroinflammation. 2011;8:35. [PMC free article] [PubMed]
77. Okugawa S, Moayeri M, Eckhaus MA, Crown D, Miller-Randolph S, Liu S, Akira S, Leppla SH. MyD88-dependent signaling protects against anthrax lethal toxin-induced impairment of intestinal barrier function. Infect Immun. 2011;79:118–124. [PMC free article] [PubMed]
78. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, Alexopoulou L, Flavell RA, Beutler B. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A. 2004;101:3516–3521. [PubMed]
79. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, Orihuela MM, Akira S, Yokoyama WM, Colonna M. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity. 2004;21:107–119. [PubMed]
80. Mansur DS, Kroon EG, Nogueira ML, Arantes RME, Rodrigues SCO, Akira S, Gazzinelli RT, Campos MA. Lethal Encephalitis in Myeloid Differentiation Factor 88-Deficient Mice Infected with Herpes Simplex Virus 1. Am J Pathol. 2005;166:1419–1426. [PubMed]
81. Zhou S, Kurt-Jones EA, Mandell L, Cerny A, Chan M, Golenbock DT, Finberg RW. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur J Immunol. 2005;35:822–830. [PubMed]
82. Delale T, Paquin A, Asselin-Paturel C, Dalod M, Brizard G, Bates EE, Kastner P, Chan S, Akira S, Vicari A, Biron CA, Trinchieri G, Briere F. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol. 2005;175:6723–6732. [PubMed]
83. Tengvall S, Harandi AM. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice. J Reprod Immunol. 2007 [PubMed]
84. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, Kawai T, Akira S. Differential Role of TLR- and RLR-Signaling in the Immune Responses to Influenza A Virus Infection and Vaccination. J Immunol. 2007;179:4711–4720. [PubMed]
85. Jung A, Kato H, Kumagai Y, Kumar H, Kawai T, Takeuchi O, Akira S. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces cytotoxic T cell response via MyD88. J Virol. 2007 [PMC free article] [PubMed]
86. Hokeness-Antonelli KL, Crane MJ, Dragoi AM, Chu WM, Salazar-Mather TP. IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J Immunol. 2007;179:6176–6183. [PubMed]
87. Lang KS, Navarini AA, Recher M, Lang PA, Heikenwalder M, Stecher B, Bergthaler A, Odermatt B, Akira S, Honda K, Hengartner H, Zinkernagel RM. MyD88 protects from lethal encephalitis during infection with vesicular stomatitis virus. Eur J Immunol. 2007;37:2434–2440. [PubMed]
88. Zhou S, Kurt-Jones EA, Fitzgerald KA, Wang JP, Cerny AM, Chan M, Finberg RW. Role of MyD88 in route-dependent susceptibility to vesicular stomatitis virus infection. J Immunol. 2007;178:5173–5181. [PubMed]
89. Sheahan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, Heise MT. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 2008;4:e1000240. [PMC free article] [PubMed]
90. Li J, Faber M, Dietzschold B, Hooper DC. The role of toll-like receptors in the induction of immune responses during rabies virus infection. Adv Virus Res. 2011;79:115–126. [PubMed]
91. Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc Natl Acad Sci U S A. 2009;106:11300–11305. [PubMed]
92. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, Medzhitov R, Sher A. Cutting Edge: MyD88 Is Required for Resistance to Toxoplasma gondii Infection and Regulates Parasite-Induced IL-12 Production by Dendritic Cells. J Immunol. 2002;168:5997–6001. [PubMed]
93. Chen M, Aosai F, Norose K, Mun HS, Takeuchi O, Akira S, Yano A. Involvement of MyD88 in host defense and the down-regulation of anti-heat shock protein 70 autoantibody formation by MyD88 in Toxoplasma gondii-infected mice. J Parasitol. 2002;88:1017–1019. [PubMed]
94. de Veer MJ, Curtis JM, Baldwin TM, DiDonato JA, Sexton A, McConville MJ, Handman E, Schofield L. MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol. 2003;33:2822–2831. [PubMed]
95. Debus A, Glasner J, Rollinghoff M, Gessner A. High levels of susceptibility and T helper 2 response in MyD88-deficient mice infected with Leishmania major are interleukin-4 dependent. Infect Immun. 2003;71:7215–7218. [PMC free article] [PubMed]
96. Mun HS, Aosai F, Norose K, Chen M, Piao LX, Takeuchi O, Akira S, Ishikura H, Yano A. TLR2 as an essential molecule for protective immunity against Toxoplasma gondii infection. Int Immunol. 2003;15:1081–1087. [PubMed]
97. Campos MA, Closel M, Valente EP, Cardoso JE, Akira S, Alvarez-Leite JI, Ropert C, Gazzinelli RT. Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J Immunol. 2004;172:1711–1718. [PubMed]
98. Hitziger N, Dellacasa I, Albiger B, Barragan A. Dissemination of Toxoplasma gondii to immunoprivileged organs and role of Toll/interleukin-1 receptor signalling for host resistance assessed by in vivo bioluminescence imaging. Cell Microbiol. 2005;7:837–848. [PubMed]
99. Drennan MB, Stijlemans B, Van den Abbeele J, Quesniaux VJ, Barkhuizen M, Brombacher F, De Baetselier P, Ryffel B, Magez S. The induction of a type 1 immune response following a Trypanosoma brucei infection is MyD88 dependent. J Immunol. 2005;175:2501–2509. [PubMed]
100. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, Sher A. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol. 2006;177:3515–3519. [PubMed]
101. Rogers KA, Rogers AB, Leav BA, Sanchez A, Vannier E, Uematsu S, Akira S, Golenbock D, Ward HD. MyD88-dependent pathways mediate resistance to Cryptosporidium parvum infection in mice. Infect Immun. 2006;74:549–556. [PMC free article] [PubMed]
102. Koga R, Hamano S, Kuwata H, Atarashi K, Ogawa M, Hisaeda H, Yamamoto M, Akira S, Himeno K, Matsumoto M, Takeda K. TLR-dependent induction of IFN-beta mediates host defense against Trypanosoma cruzi. J Immunol. 2006;177:7059–7066. [PubMed]
103. Sukhumavasi W, Egan CE, Warren AL, Taylor GA, Fox BA, Bzik DJ, Denkers EY. TLR adaptor MyD88 is essential for pathogen control during oral toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J Immunol. 2008;181:3464–3473. [PMC free article] [PubMed]
104. Vargas-Inchaustegui DA, Tai W, Xin L, Hogg AE, Corry DB, Soong L. Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect Immun. 2009;77:2948–2956. [PMC free article] [PubMed]
105. Revaz-Breton M, Ronet C, Ives A, Torre YH, Masina S, Tacchini-Cottier F, Launois P. The MyD88 protein 88 pathway is differently involved in immune responses induced by distinct substrains of Leishmania major. Eur J Immunol. 2010;40:1697–1707. [PubMed]
106. Hou B, Benson A, Kuzmich L, DeFranco AL, Yarovinsky F. Critical coordination of innate immune defense against Toxoplasma gondii by dendritic cells responding via their Toll-like receptors. Proc Natl Acad Sci U S A. 2011;108:278–283. [PubMed]
107. Zhang Q, Feng X, Nie W, Golenbock DT, Mayanja-Kizza H, Tzipori S, Feng H. MyD88-dependent pathway is essential for the innate immunity to Enterocytozoon bieneusi. Parasite Immunol. 2011;33:217–225. [PMC free article] [PubMed]
108. Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS, Vecchi A, Mantovani A, Levitz SM, Romani L. The Contribution of the Toll-Like/IL-1 Receptor Superfamily to Innate and Adaptive Immunity to Fungal Pathogens In Vivo. J Immunol. 2004;172:3059–3069. [PubMed]
109. Villamon E, Gozalbo D, Roig P, Murciano C, O’Connor JE, Fradelizi D, Gil ML. Myeloid differentiation factor 88 (MyD88) is required for murine resistance to Candida albicans and is critically involved in Candida-induced production of cytokines. Eur Cytokine Netw. 2004;15:263–271. [PubMed]
110. Yauch LE, Mansour MK, Shoham S, Rottman JB, Levitz SM. Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun. 2004;72:5373–5382. [PMC free article] [PubMed]
111. Biondo C, Midiri A, Messina L, Tomasello F, Garufi G, Catania MR, Bombaci M, Beninati C, Teti G, Mancuso G. MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. Eur J Immunol. 2005;35:870–878. [PubMed]
112. De Luca A, Montagnoli C, Zelante T, Bonifazi P, Bozza S, Moretti S, D’Angelo C, Vacca C, Boon L, Bistoni F, Puccetti P, Fallarino F, Romani L. Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J Immunol. 2007;179:5999–6008. [PubMed]
113. Loures FV, Pina A, Felonato M, Feriotti C, de Araujo EF, Calich VL. MyD88 signaling is required for efficient innate and adaptive immune responses to Paracoccidioides brasiliensis infection. Infect Immun. 2011;79:2470–2480. [PMC free article] [PubMed]
114. Kuhns DB, Long Priel DA, Gallin JI. Endotoxin and IL-1 hyporesponsiveness in a patient with recurrent bacterial infections. J Immunol. 1997;158:3959–3964. [PubMed]
115. Haraguchi S, Day NK, Nelson RP, Jr, Emmanuel P, Duplantier JE, Christodoulou CS, Good RA. Interleukin 12 deficiency associated with recurrent infections. Proc Natl Acad Sci U S A. 1998;95:13125–13129. [PubMed]
116. Medvedev AE, Lentschat A, Kuhns DB, Blanco JC, Salkowski C, Zhang S, Arditi M, Gallin JI, Vogel SN. Distinct Mutations in IRAK-4 Confer Hyporesponsiveness to Lipopolysaccharide and Interleukin-1 in a Patient with Recurrent Bacterial Infections. J Exp Med. 2003;198:521–531. [PMC free article] [PubMed]
117. Day N, Tangsinmankong N, Ochs H, Rucker R, Picard C, Casanova JL, Haraguchi S, Good R. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J Pediatr. 2004;144:524–526. [PubMed]
118. Enders A, Pannicke U, Berner R, Henneke P, Radlinger K, Schwarz K, Ehl S. Two siblings with lethal pneumococcal meningitis in a family with a mutation in Interleukin-1 receptor-associated kinase 4. J Pediatr. 2004;145:698–700. [PubMed]
119. Chapel H, Puel A, von Bernuth H, Picard C, Casanova JL. Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. Clin Infect Dis. 2005;40:1227–1231. [PubMed]
120. McDonald DR, Brown D, Bonilla FA, Geha RS. Interleukin receptor-associated kinase-4 deficiency impairs Toll-like receptor-dependent innate antiviral immune responses. J Allergy Clin Immunol. 2006;118:1357–1362. [PubMed]
121. Cardenes M, von Bernuth H, Garcia-Saavedra A, Santiago E, Puel A, Ku CL, Emile JF, Picard C, Casanova JL, Colino E, Bordes A, Garfia A, Rodriguez-Gallego C. Autosomal recessive interleukin-1 receptor-associated kinase 4 deficiency in fourth-degree relatives. J Pediatr. 2006;148:549–551. [PubMed]
122. Davidson DJ, Currie AJ, Bowdish DM, Brown KL, Rosenberger CM, Ma RC, Bylund J, Campsall PA, Puel A, Picard C, Casanova JL, Turvey SE, Hancock RE, Devon RS, Speert DP. IRAK-4 Mutation (Q293X): Rapid Detection and Characterization of Defective Post-Transcriptional TLR/IL-1R Responses in Human Myeloid and Non-Myeloid Cells. J Immunol. 2006;177:8202–8211. [PMC free article] [PubMed]
123. Takada H, Yoshikawa H, Imaizumi M, Kitamura T, Takeyama J, Kumaki S, Nomura A, Hara T. Delayed separation of the umbilical cord in two siblings with Interleukin-1 receptor-associated kinase 4 deficiency: rapid screening by flow cytometer. J Pediatr. 2006;148:546–548. [PubMed]
124. Szabo J, Dobay O, Erdos M, Borbely A, Rozgonyi F, Marodi L. Recurrent infection with genetically identical pneumococcal isolates in a patient with interleukin-1 receptor-associated kinase-4 deficiency. J Med Microbiol. 2007;56:863–865. [PubMed]
125. Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, Chrabieh M, Issekutz AC, Cunningham CK, Gallin J, Holland SM, Roifman C, Ehl S, Smart J, Tang M, Barrat FJ, Levy O, McDonald D, Day-Good NK, Miller R, Takada H, Hara T, Al-Hajjar S, Al-Ghonaium A, Speert D, Sanlaville D, Li X, Geissmann F, Vivier E, Marodi L, Garty BZ, Chapel H, Rodriguez-Gallego C, Bossuyt X, Abel L, Puel A, Casanova JL. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med. 2007;204:2407–2422. [PMC free article] [PubMed]
126. Comeau JL, Lin TJ, Macken MB, Li B, Ku CL, von Bernuth H, Casanova JL, Issekutz AC. Staphylococcal Pericarditis, and Liver and Paratracheal Abscesses as Presentations in Two New Cases of Interleukin-1 Receptor Associated Kinase 4 Deficiency. Pediatr Infect Dis J. 2008;27:170–174. [PubMed]
127. Krause JC, Ghandil P, Chrabieh M, Casanova JL, Picard C, Puel A, Creech CB. Very late-onset group B Streptococcus meningitis, sepsis, and systemic shigellosis due to interleukin-1 receptor-associated kinase-4 deficiency. Clin Infect Dis. 2009;49:1393–1396. [PubMed]
128. Conway DH, Dara J, Bagashev A, Sullivan KE. Myeloid differentiation primary response gene 88 (MyD88) deficiency in a large kindred. J Allergy Clin Immunol. 2010;126:172–175. [PubMed]
129. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clin Microbiol Rev. 2011;24:490–497. [PMC free article] [PubMed]
130. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K. Genetic analysis of host resistance: Toll-like receptor signlling and immunity at large. Ann Rev Immunol. 2006;24:353–89. [PubMed]
131. Davis MM. A prescription for human immunology. Immunity. 2008;29:835–838. [PMC free article] [PubMed]
132. Hayday AC, Peakman M. The habitual, diverse and surmountable obstacles to human immunology research. Nat Immunol. 2008;9:575–580. [PubMed]
133. Davis MM. Immunology taught by humans. Sci Transl Med. 2012;4:117fs112. [PMC free article] [PubMed]